Clinical Aerospace Medicine: Certification, Fitness, and Patient Care
Certification as risk assessment
Clinical aerospace medicine is not ordinary primary care delivered at an airport. The core task is predicting whether a person can perform safety-critical duties without sudden incapacitation, degraded consciousness, or impaired cognition and vision. Certification rests on three legs: history, examination, and a documented risk estimate. Know the difference between regulatory standards (ICAO Annex 1 sets minimum international requirements; national authorities such as FAA and EASA implement them with local differences) and clinical guidelines, which advise but do not certify.
High-yield conditions
Cardiovascular disease dominates: hypertension, arrhythmia, coronary artery disease, syncope, and anticoagulation. Neurologic issues include seizure, migraine, vestibular disease, and head injury. Psychiatric conditions, especially depression and substance use, require careful assessment of recurrence risk and medication effects. Vision and hearing standards vary by certificate class. Treatable chronic conditions such as obstructive sleep apnea, diabetes, and asthma are frequently certifiable when stable, monitored, and free of end-organ complications.
Traps candidates fall for
- Assuming a diagnosis permanently grounds a pilot. Waivers and special issuance exist.
- Confusing ICAO minimum standards with stricter national rules.
- Forgetting the airman's self-grounding duty and obligation to report changes.
- Assuming a drug is acceptable because it is common; many cause sedation or subtle cognitive slowing.
- Overlooking time-limited re-evaluation and monitoring conditions attached to a waiver.
Rule of thumb and worked example
Rule: any condition that could produce sudden incapacitation or degrade consciousness, cognition, or vision in a safety-critical role is disqualifying until a waiver demonstrates acceptable risk. Example: a 45-year-old airline pilot with newly diagnosed uncomplicated hypertension, no end-organ damage, on a single well-tolerated agent, is generally eligible after a documented observation period; uncontrolled or symptomatic disease is not.